Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase... by Galle, Peter R, Prof, Finn, Richard S, Prof, Qin, Shukui, Prof, Ikeda, Masafumi, MD, Zhu, Andrew X, Prof, Kim, Tae-You, Prof, Kudo, Masatoshi, Prof, Breder, Valeriy, MD, Merle, Philippe, Prof, Kaseb, Ahmed, Prof, Li, Daneng, MD, Mulla, Sohail, PhD, Verret, Wendy, PhD, Xu, Derek-Zhen, MD, Hernandez, Sairy, PhD, Ding, Beiying, PhD, Liu, Juan, PhD, Huang, Chen, MD, Lim, Ho Yeong, Prof, Cheng, Ann-Lii, Prof, Ducreux, Michel, Prof

Get full text